Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Aspira Pathlab & Diagnostics EBITDA Margin % Related Terms
Aspira Pathlab & Diagnostics EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540788 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Aspira Pathlab & Diagnostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Pathlab & Diagnostics EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Pathlab & Diagnostics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Aspira Pathlab & Diagnostics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Pathlab & Diagnostics (BOM:540788) has a EBITDA Margin % of -2.97% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aspira Pathlab & Diagnostics and its competitors. According to the industry distribution chart, Aspira Pathlab & Diagnostics ranks #95 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 46.8%.
Is Aspira Pathlab & Diagnostics' EBITDA Margin % too high?
Aspira Pathlab & Diagnostics' current EBITDA Margin % is -2.97%. Based on the distribution chart, Aspira Pathlab & Diagnostics ranks #95 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Aspira Pathlab & Diagnostics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Pathlab & Diagnostics' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Pathlab & Diagnostics ranks #95 out of 203 companies for EBITDA Margin %. This puts Aspira Pathlab & Diagnostics in the upper half of its industry. The industry median EBITDA Margin % is 5.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.43, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aspira Pathlab & Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Pathlab & Diagnostics's current EBITDA Margin % is -2.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Pathlab & Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics (BOM:540788) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹70.73, compared to a current price of ₹106.90 — trading 51.1% above its estimated fair value. The current EBITDA Margin % is -2.97%. Aspira Pathlab & Diagnostics' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aspira Pathlab & Diagnostics (BOM:540788), the current EBITDA Margin % is -2.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Pathlab & Diagnostics (BOM:540788) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics stock appears to be overvalued.
The current stock price of ₹106.90 is trading 51.1% above its estimated GF Value™ of ₹70.73.
GuruFocus considers Aspira Pathlab & Diagnostics to be Significantly Overvalued.
Key valuation signals for BOM:540788:
EBITDA Margin %: -2.97%
GF Value™: ₹70.73 vs. price of ₹106.90 (51.1% above fair value)
No single metric tells the full story. See the BOM:540788 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Pathlab & Diagnostics Ltd is mainly engaged in pathology and related healthcare services. It operates laboratories that conduct a wide range of pathological investigations across branches such as biochemistry, hematology, histopathology, microbiology, immunochemistry, immunology, virology, cytology, and other pathological and radiological tests. The services offered include pathology tests, sonography, X-rays, and radiology. The company also provides various health packages like gynecology profiles, anemia profiles, monsoon profiles, coagulation tests, cancer screening packages, newborn screening and IEM panels, orthopedic profiles, allergy panels, and cardiac profiles. These comprehensive diagnostic services assist in disease diagnosis.
51GF Score
Get the complete analysis for BOM:540788
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540788 has been successfully added to your 
